Wedbush Downgrades Chinook Therapeutics to Neutral, Announces $42 Price Target
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Laura Chico has downgraded Chinook Therapeutics (NASDAQ:KDNY) from Outperform to Neutral and set a price target of $42.
August 08, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Chinook Therapeutics has been downgraded from Outperform to Neutral by Wedbush, with a price target of $42.
The downgrade from Outperform to Neutral by Wedbush indicates a less optimistic outlook for Chinook Therapeutics. This could potentially lead to a decrease in the stock's price in the short term. The price target of $42 provides a benchmark for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100